** Kotak starts coverage on India's Dr Agarwal's Health Care DRAA.NS with "add" and a fair value of 425 rupees
** Brokerage says high-priced surgical cases, which comprise 62%-65% of the total cases, will boost overall revenue for the eye care services provider over FY28
** Kotak's PT represents a 7.6% upside to DRAA's current price of 394.85 rupees; however, stock down 2% on the day
** Adds, DRAA's strong EBITDA growth trajectory broadly compensates for its currently lower, albeit, improving margins
** Avg rating of three analysts, excluding Kotak, at "buy"; median PT is 502 rupees - data compiled by LSEG
** Stock down 1.7% since trading debut in February
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))